Tags : Three

Biotech COVID-19 M&A

Merck Reports Three Major Initiatives Focusing on Developing Vaccine Against

Shots: Merck will acquire all outstanding shares of Themis in exchange for an undisclosed cash payment. The acquisition follows the ongoing collaboration between the two companies to develop vaccine candidates utilizing the measles virus vector platform and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate with the anticipated initiation of clinical study […]Read More

Pharma

Bayer Signs a Three Year Multi Target AI-based Agreement with

Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration   The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for […]Read More

Biosimilars

Yas Holding to Acquire Stake in Alvotech and Signs an

Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar candidates in MENA region The investment will complement Yas holding an existing portfolio and expands its footprints in health & pharmaceutical sector both in the […]Read More

Biosimilars

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

Biotech

ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the

Shots: ImaginAb signs a multi-year agreement with AstraZeneca, Pfizer & Takeda for the development of ImaginAb’s CD8 ImmunoPET technology. The global companies will get early access to clinical and imaging data & will contribute in post-trial data analysis in exchange for helping ImaginAb’s current clinical studies The focus of the agreement is to streamline the […]Read More

Pharma

Allergan to Launch Three REFRESH RELIEVA Lubricant Eye Drops Expanding

Shots: Allergan launches three new OTC REFRESH RELIEVA products: REFRESH RELIEVA, REFRESH RELIEVA PF multidose and REFRESH RELIEVA for contacts to relieve discomfort due to eye dryness and to prevent irritation The launch of three unique options to treat patients with dry, irritated eyes and contact lens dryness expands Allergan’s artificial tear, REFRESH portfolio. REFRESH […]Read More